4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $36.00 price objective on the stock.
Several other research analysts have also recently issued reports on the stock. Royal Bank of Canada decreased their price objective on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a report on Thursday, November 14th. Leerink Partners decreased their price objective on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a report on Monday, January 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Saturday, February 1st. BMO Capital Markets cut shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $40.00 to $15.00 in a report on Monday, January 13th. Finally, Chardan Capital reiterated a “buy” rating and issued a $39.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $32.13.
View Our Latest Stock Analysis on FDMT
4D Molecular Therapeutics Price Performance
Institutional Investors Weigh In On 4D Molecular Therapeutics
Several hedge funds have recently made changes to their positions in FDMT. The Manufacturers Life Insurance Company lifted its position in shares of 4D Molecular Therapeutics by 25.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,975 shares of the company’s stock valued at $398,000 after acquiring an additional 3,850 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter valued at approximately $321,000. nVerses Capital LLC purchased a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter valued at approximately $40,000. Assenagon Asset Management S.A. lifted its position in shares of 4D Molecular Therapeutics by 238.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,543,414 shares of the company’s stock valued at $16,684,000 after acquiring an additional 1,087,147 shares in the last quarter. Finally, Values First Advisors Inc. purchased a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter valued at approximately $57,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.
About 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
Further Reading
- Five stocks we like better than 4D Molecular Therapeutics
- 5 Top Rated Dividend Stocks to Consider
- META Stock: Insider Selling Ramps Up—What It Means for Investors
- Investing in the High PE Growth Stocks
- 3 Chip Stocks Still Trading 50% Below Their 52-Week Highs
- 3 REITs to Buy and Hold for the Long Term
- U.S. Steel: Will Trump-Backed Nippon Investment Drive Upside?
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.